WG
PLX icon

Winton Group’s Protalix BioTherapeutics PLX Stock Holding History

Winton Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
+56,001
New +$119K ﹤0.01% 1062

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Winton Group's PLX Position: Q2 2026 in Review

Winton Group opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 56,001 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #1062 among its holdings.

37 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Winton Group held 56,001 shares of Protalix BioTherapeutics worth $130K as of Q2 2026.
  • Protalix BioTherapeutics was a new Winton Group position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1062 holding.
  • 37 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.